Medtronic (NYSE: MDT) Price Target Raised to $115 Amid Strong Q1 Earnings and Strategic Growth
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameAbattis Bioceuticals Corp.
-
Registration countryCanada
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









